Waters Corporation, which trades under the ticker symbol WAT, is an America-based prominent player in the Life Science Tools & Services industry renowned for its vast spectrum of product offerings and collaborations. The company was established in 1958 and is headquartered in Milford, Massachusetts.
Primarily, Waters Corp operates through two business segments: Waters and TA. The 'Waters' segment primarily manufactures and sells high-performance liquid chromatography (HPLC), ultra-performance liquid chromatography (UPLC), and mass spectrometry (MS) technology systems and support products, including software and reagents. These tools are used by pharmaceutical, life science, biochemical, industrial, academic, and governmental customers working in research and development, quality assurance, and other laboratory applications.
The 'TA' segment designs, manufactures, sells, and supports thermal analysis, rheometry, and calorimetry instruments. These instruments are used in predicting the suitability and stability of fine chemicals, pharmaceuticals, water, polymers, metals, and viscous liquids for various industrial, consumer goods, and healthcare products.
Waters Corp's growth strategy largely involves product innovation in chromatography and mass spectrometry, focusing on enhancing commercial execution, leveraging service opportunities, and investing in applied and emerging markets. They believe in the philosophy of 'Deliver Benefit' which aims to improve human health and well-being.
The company's market reach is not limited within the boundaries of the United States. It caters to a wide range of clientele globally, thus making it an influential entity in the global life science tools & services sphere. Waters Corp has managed to forge a strong identity in its field through its commitment to visionary science and sustained high-quality customer service.
Despite various challenges posed by the transforming global landscape, Waters Corporation has maintained a solid financial profile. It's listed on the New York Stock Exchange (NYSE) and is included in the S&P 400 index, indicative of the firm's reputable standing in capital markets and among investors.
The company also demonstrates its commitment to corporate social responsibility through endeavors such as the Waters Charitable Foundation, which focuses on supporting students from kindergarten through college to engage and succeed in STEM education.
Overall, Waters Corp (WAT) has demonstrated consistent performance and remained a big name in life science technology, marking its presence with high-quality products and innovations that contribute significantly to scientific advancement.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Argus has lowered its target price for STERIS plc (Ireland) (STE) to $230.00. STERIS is a medical technology company specializing in sterilization services and infection prevention. The report was published on September 23, 2026.
This article examines the investment performance of Agilent Technologies (A) over the past decade. A $1000 investment in Agilent Technologies ten years ago would now be worth $3,583.89, representing a 258.39% gain, outperforming both the S&P 500 and gold over the same period. Analysts are optimistic about Agilent's future, citing sustained instrument demand, pharma exposure, and recent product launches.
Waters (NYSE: WAT) has significantly outperformed the market over the last 20 years, achieving an average annual return of 11.74%. An initial investment of $1000 in WAT stock two decades ago would now be valued at $9,062.58. This illustrates the substantial impact of compounded returns on investment growth over time.
Jonathan M. Pratt has taken over as CEO of Qiagen N.V., succeeding Thierry Bernard who led the company for nearly seven years. Pratt brings over 25 years of international leadership experience in the life sciences and healthcare sectors, having previously served in senior roles at Filtration Group, Waters Corporation, and Beckman Coulter Life Sciences. Bernard will assist with the transition until the end of the year.